Comparative Pharmacology
Head-to-head clinical analysis: METAHYDRIN versus RESNIBEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METAHYDRIN versus RESNIBEN.
METAHYDRIN vs RESNIBEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
RESNIBEN is a selective inhibitor of the sodium-glucose cotransporter-2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
1 mg orally once daily, increased to 2 mg once daily based on response and tolerability; maximum 2 mg daily.
None Documented
None Documented
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Terminal elimination half-life is 6-8 hours in healthy adults, prolonged to 12-15 hours in renal impairment (CrCl <30 mL/min).
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Primarily renal excretion (65-70% as unchanged drug), with biliary/fecal elimination accounting for 20-25% (including metabolites).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic